Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials

Liou, 2001, Predictive 5-year survivorship model of cystic fibrosis, Am J Epidemiol, 153, 345, 10.1093/aje/153.4.345

Britto, 2002, Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis, Chest, 121, 64, 10.1378/chest.121.1.64

Fuchs, 1994, Effect of aerosolized re-combinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group, N Engl J Med, 331, 637, 10.1056/NEJM199409083311003

Ramsey, 1999, Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group, N Engl J Med, 340, 23, 10.1056/NEJM199901073400104

Saiman, 2003, Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial, JAMA, 290, 1749, 10.1001/jama.290.13.1749

Elkins, 2006, A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis, N Engl J Med, 354, 229, 10.1056/NEJMoa043900

Dakin, 2001, Defining an exacerbation of pulmonary disease in cystic fibrosis, Pediatr Pulmonol, 31, 436, 10.1002/ppul.1072

Rosenfeld, 2001, Defining a pulmonary exacerbation in cystic fibrosis, J Pediatr, 139, 359, 10.1067/mpd.2001.117288

Rabin, 2004, Pulmonary exacerbations in cystic fibrosis, Pediatr Pulmonol, 37, 400, 10.1002/ppul.20023